5de Gasparo M, Joss L, Ran Jou HP, et M. Three new epoxyspinolactone derivatives characterization in vivo and in vitro [ J ]. Pharmacol Exp Ther, 1987, 240(2) : 650-656.
6Pitt B, Zannad F, Rammme W J, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators [ J ]. N EnglJ Med, 1999, 341(10) : 709-717.
7Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker in patients with left ventricular dysfunction after myocardial infarction [ J ]. N Engl Med J, 2003, 348(14) : 1309-1321.
6Rossi GP, Seccia TM, Maniero C, et al. Drug-related hyperten- sion and resistance to antihypertensive treatment: a call for action [J]. JHypertens, 2011, 29(12): 2295-2309.
7Grossman E, Messerli FH. Drug-induced hypertension: an un- appreciated cause of secondary hypertension [ J ]. Am J Med, 2012, 125 ( 1 ) : 14-22.
8Tisdale JE, Miller DA. Drug-induced diseases: prevention, de- tection, and mamagement M . 2nd Edition. Bethesda: Ameri- can Society of Health-System Pharmacists, 2010 : 519.
9Morrison A, Ramey DR, van Adelsberg J, et al. Systematic re- view of trials of the effect of continued use of oral non-selective NSAIDs on blood pressure and hypertension[ J]. Curr Med Res Opin, 2007, 23(10): 2395-2404.
10William BW, Campbell P. Blood pressure destabilization on non- steroidal anti-inflammatory agents: acetaminophen exposed I J ]. Circulation, 2010, 122 (18) : 1779-1781.
